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Inhibition of Th1 Development Mediated by GATA-3
through an IL-4-Independent Mechanism
c-maf (Ho et al., 1996) and GATA-3 (Zheng and Flavell,
1997) as Th2-specific transcription factors. C-maf ex-
pression is selectively increased in Th2 development
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and Kenneth M. Murphy*³ and interacts directly with the proximal IL-4 promoter
*Department of Pathology at the MARE element to augment transcription (Ho et
and Center for Immunology al., 1996). GATA-3, also expressed by naive and Th2 cells
Howard Hughes Medical Institute but not Th1 cells, was shown to augment transcription of
Washington University School of Medicine the IL-4 and IL-5 genes (Zhang et al., 1997; Zheng and
St. Louis, Missouri 63110 Flavell, 1997; Lee et al., 1998). The basis for Th2-selec-
²Molecular and Cell Biology Department tive expression of these transcription factors is not yet
University of California, Berkeley understood in terms of responses to cytokines such
Berkeley, California 94720-3200 as IL-12 and IL-4 that control T helper development.
Nonetheless, collectively c-maf and GATA-3 provide a
basis for the positive regulation of several Th2-specific
Summary cytokine genes.
In contrast, the basis for Th1-selective expression of
Recently, the transcription factor GATA-3 was shown IFNg has not yet been firmly linked to IL-12 or to Stat4.
to be selectively expressed in Th2 but not Th1 cells Studies of IFNg regulation have identified several poten-
and to augment Th2-specific cytokines. Here, we show tial positive and negative cis-acting regulatory elements
that loss of GATA-3 expression by developing Th1 cells (Young and Hardy, 1995). However, most current infor-
requires IL-12 signaling through Stat4 and does not mation is based on transformed tumor models, and
simply result from an absence of IL-4. Moreover, we which of these elements operate in Th1/Th2 regulation
demonstrate a novel role for GATA-3 in directly re- has not been addressed. A proximal element interacts
pressing Th1 development distinct from its positive with CREB/ATF1 transcription factors, but these factors
actions on Th2-specific cytokines. GATA-3 inhibits Th1 have not been described as acting in a subset-restricted
cytokines by a cell-intrinsic mechanism that is not manner (Cippitelli et al., 1995; Penix et al., 1996). Another
dependent on IL-4 and that may involve repression of study reported a positive GATA-3 interaction with a dis-
IL-12 signaling. Thus, GATA-3 expression and IL-12 tal IFNg promoter element (Penix et al., 1993) but pre-
signaling are mutually antagonistic, which facilitates ceded the recognition that GATA-3 was present in Th2
rapid dominance of one pathway during early Th devel- but not Th1 cells. The potential repressor YY-1 was
opment, producing a stable divergence in cytokine shown to interact with an element in the proximal IFNg
profiles. promoter (Ye et al., 1996), but it has not been shown to
be differentially regulated between Th1 and Th2 cells.
Introduction Young and colleagues identified a class of sites inter-
acting with NF-kB and possibly NF-AT factors (Sica et
Interferon g (IFNg) protects against many viral and intra-
al., 1997). Several elements in the promoter and first
cellular pathogens through pleiotropic effects on both
intron of the IFNg gene were identified that could poten-innate and specific immune cells (Bach et al., 1997).
tially interact with STAT factors (Xu et al., 1996). ManyAmong the important sources of IFNg are natural killer
of these elements were nonconsensus STAT elements(NK) cells, CD81 cytolytic T cells, and the CD41 T helper
that weakly interacted with several STAT factors, includ-(Th) 1 subset. NK cells and CD81 T cells rapidly produce
ing Stat1, Stat4, and Stat6. The direct role for Stat4IFNg following primary activation, whereas CD41 T cells
at these sites in Th1-specific IFNg expression was notundergo a period of development that determines whether
established.type I or II cytokines are produced (Abbas et al., 1996).
Here, we report several novel findings. First, we de-Important for Th1 development is interleukin-12 (IL-12)
scribe a new Stat4-dependent process by which IL-12(Hsieh et al., 1993b; Manetti et al., 1993) produced by
can augment IFNg in CD41 T cells. We show that IL-12activated macrophages and dendritic cells (Macatonia
signaling via Stat4 is required for full repression ofet al., 1993, 1995; de Saint-Vis et al., 1998), which acts
GATA-3 in Th1 cells and in turn that GATA-3 acts as athrough a mechanism involving Stat4 (Bacon et al., 1995;
repressor of Th1 development and IFNg production. TheJacobson et al., 1995; Kaplan et al., 1996; Thierfelder
inhibition by GATA-3 of IFNg production is not simply aet al., 1996). At present, little is known regarding the
secondary effect of GATA-3 on IL-4 production, sincemechanism by which Stat4 activation influences the
it occurs equally in IL-4-deficient T cells and by a cell-early differentiation processes that regulate IFNg pro-
duction by CD41 T cells. autonomous mechanism. Second, we show that GATA-3
Recently, a molecular basis of subset-restricted IL-4 represses IFNg production only when continuously ex-
production has been proposed by the identification of pressed during initial naive T cell development but not
when reintroduced into Th1 cells after IL-12-induced
Th1 development. This suggests GATA-3 may regulate³ To whom correspondence should be addressed (email: murphy@
immunology.wustl.edu). an early step in Th1 development rather than directly
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Results
Complete Repression of GATA-3 in Developing
Naive CD41 T Cells Requires IL-12 and Stat4
GATA-3 was recently shown to be a Th2-specific factor
that could positively regulate the transcription of both
IL-4 and IL-5 (Zhang et al., 1997; Zheng and Flavell,
1997; Lee et al., 1998). Zheng and colleagues used RT-
PCR to show that GATA-3 was present in naive T cells
and is increased during Th2 development and extin-
guished during Th1 development. The loss of GATA-3
during Th1 development could result either because IL-4
is required for its maintenance or because IL-12 is re-
quired for its suppression. To distinguish these possibili-
ties we examined GATA-3 expression during develop-
ment of naive CD41 T cells activated under a variety of
conditions (Figure 1).
First, GATA-3 expression is maintained even when
developing T cells are activated in the absence of IL-4
and IL-12 (Figure 1A, lane 3), a condition that does not
generate IL-4-producing T cells. GATA-3 is enhanced
by IL-4 addition (lane 4) consistent with the results of
Zheng et al. (1997). IFNg slightly reduced GATA-3 ex-
pression (Figure 1A, lanes 2 and 3), but addition of IL-12
produced complete loss of GATA-3 mRNA (lane 1). The
complete extinction of GATA-3 mRNA caused by IL-12
involves both Stat4 and Stat1 (Figure 1A, lanes 5±8).
In DO11.10 T cells lacking either Stat1 or Stat4, IL-12
treatment did not completely repress GATA-3 (Figure
1A, lanes 5 and 7), but rather GATA-3 mRNA remained
at a level similar to T cells not exposed to IL-12.
Because the effects of IL-12 were potentially a result
secondary to changes in IL-4 levels rather than direct
effects of IL-12 signaling, we repeated these experi-
ments using DO11.10 mice crossed to the IL-4-deficient
background (Figure 1B). IL-12 inhibited GATA-3 expres-
sion in wild-type DO11.10 T cells (Figure 1B, lanes 1
and 2) as before but also in IL-4-deficient T cells (lanes
3 and 4). Notably, the maintenance of GATA-3 expres-
Figure 1. IL-12 Inhibits GATA-3 Expression during Th1 Devel-
sion in T cells is not dependent on the presence of IL-4opment
during early activation of primary cells (Figure 1B, lane(A) T cells from wild-type (WT), Stat1(2/2), or Stat4(2/2) DO11.10
5). Similarly, in concanavalin A (Con A)-activated Stat6-TCR-transgenic mice were stimulated with 0.3 mM OVA peptide in
deficient T cells, we observed that IL-12 reduced GATA-3the presence of the indicated cytokines (1) or anti-cytokine antibod-
ies (-) for 48 hr and harvested, and Northern analysis was performed expression, (Figure 1B, lanes 7±9). Finally, Western anal-
as described in Experimental Procedures. ysis confirmed that IL-12 dramatically inhibited GATA-3
(B) T cells from wild-type and IL-4 (2/2) DO11.10 TCR-transgenic protein expression independently of IL-4 (Figure 1C).
mice were stimulated with OVA in the presence of the indicated
Repression of GATA-3 protein by IL-12 occurred in IL-cytokines (1) or anti-cytokines antibodies (-), or without addition
4-deficient T cells as well as in Stat6-deficient T cells(φ) for 48 hr. Con A was used to stimulate splenocytes purified from
(lane 7). High levels of GATA-3 expression induced byStat6(2/2) mice not transgenic for DO11.10 TCR. Total RNA was
extracted 48 hr later. Northern analysis was done as in (A). IL-4 appeared Stat6-dependent (Figure 1B, lanes 8 and
(C) T cells (107 cells/lane) from (B) were analyzed by Western blot 9; Figure 1C, lanes 8 and 9) as well.
for GATA-3 protein expression.
GATA-3 Expression Blocks Th1 Development
and IFNg Production Independently of IL-4repressing the IFNg promoter. This is supported by our
data that GATA-3 inhibits IL-12 receptor expression but The IL-12-dependent inhibition of GATA-3 suggests a
reciprocal repressive role for GATA-3 in Th1 develop-does not inhibit reporter activity of the IFNg promoter.
Finally, reintroduction of GATA-3 into Th1 cells, even ment. To test this, we wished to maintain GATA-3 ex-
pression during IL-12-induced Th1 development. Weas early as 7 days after priming, fails to induce IL-4
expression, suggesting that GATA-3 alone is not suffi- generated a bi-cistronic retrovirus coexpressing GATA-3
and GFP (Figure 2A). This retrovirus expresses GATA-3cient to induce IL-4 production and may be required to
act during a temporally restricted window of devel- under control of MSCV LTR that is not inhibited by IL-12,
thus maintaining GATA-3 expression during early T cellopment.
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Figure 2. GATA-3 Inhibits IL-12-Induced Th1 Development and IFNg Production
(A) Retroviral constructs. The retrovirus vector containing only GFP (GFP-RV) was used in all experiments to control for the effects of retrovirus
infection. The GATA-3-expressing retrovirus (GATA3-RV) contains murine GATA-3 cDNA placed behind the murine stem cell virus (MSCV)
long terminal repeat (LTR) and upstream of the internal ribosomal entry site (IRES) from encephalomyocarditis virus in GFP-RV.
(B) DO11.10 TCR-transgenic T cells were infected on day 1 of primary activation by either control (GFP-RV) or GATA-3-expressing (GATA3-
RV) retrovirus, treated using Th1-inducing and Th2-inducing conditions as indicated (Experimental Procedures), harvested on day 7, stained
with anti-CD4-PE (Pharmingen), and analyzed by two-color FACS. Numbers represent the quadrant statistics of live-gated events. These cells
were then sorted for GFP/CD4 expression.
(C) GFP-positive T cells that were sorted from the indicated populations in (B) were reactivated with OVA/APCs and analyzed after 3 days for
GFP expression by FACS. Data is presented as single-color histograms of live gated events. The negative control (untransfected) was a
noninfected parallel Th1 culture from the same experiment.
(D) GATA-3 expression in the sorted populations from (C) was determined by Western analysis 7 days after restimulation. 107 T cells from the
indicated transfection were stimulated by PMA and ionomycin for 4 hr before lysis for Western analysis for GATA-3.
(E) DO11.10 TCR-transgenic primary T cells were activated under either Th1 or Th2 conditions as indicated and infected by GFP-RV, GATA3-
RV on day 1. GPF1 CD41 T cells were purified by cell sorting on day 7 and stimulated with OVA and APCs, expanded for 7 days, harvested,
washed, and stimulated at 1.25 3 105/ml with 0.3 mM OVA and irradiated BALB/c splenocytes as APCs. Supernatants were harvested after
48 hr and IFNg and IL-4 production determined by ELISA as described. Similar results were obtained in six other independent retroviral
transfection experiments.
development. Naive T cells were activated with antigen to that of Th2 cells (Figure 2E). Further, GATA-3 expres-
sion in IL-4-treated T cells did not increase IL-4 produc-under conditions to induce either Th1 or Th2 develop-
ment and were infected with retrovirus on day 1 after tion above control Th2 levels. To explore potential mech-
anisms of this GATA-3 action, we examined a mutantprimary activation. Cells were allowed to develop until
day 7, when retroviral infection was determined by mea- form of GATA-3, KRR. In this mutant, amino acids 305±
307 (KRR), located just before the second zinc fingersuring GFP expression (Figure 2B) and infected cells
were purified by cell sorting. CD41 GFP1 TCR transgenic domain, are changed to AAA (Smith et al., 1995). This
mutant was reported to exert a dominant negative effectT cells were purified to greater than 95% (Figure 2C).
Expression of GATA-3 under LTR control achieved levels on a synthetic reporter construct containing multimers
of GATA elements (Smith et al., 1995) but to retain theof protein expression very similar to levels expressed by
native Th2 cells (Figure 2D), both in wild-type DO11.10 T ability to bind DNA. Expression of the KRR GATA-3 mu-
tant in IL-12-treated developing Th1 cells caused thecells (compare lanes 2 and 3) and in IL-4-deficient
DO11.10 T cells (lanes 5 and 6). To control for any effect same total reduction in IFNg and slight IL-4 augmen-
tation as wild-type GATA-3 (Figure 2E). This suggestsof virus infection itself, all experiments were done using
GATA-3-expressing retrovirus (GATA-3-RV) and empty- that the relevant GATA-3 target sites in developing T
cells are not affected by the KRR mutation unlike theretrovirus expressing only GFP (GFP-RV) as a control.
Maintenance of GATA-3 expression in IL-12-treated multimerized GATA reporters used previously (Smith et
al., 1995), but nonetheless reinforces the results seendeveloping T cells virtually eliminated subsequent IFNg
production (Figure 2E). This also modestly augmented for wild-type GATA-3.
To determine if the inhibition of IL-12-induced IFNgIL-4 production but did not fully increase levels of IL-4
Immunity
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Figure 3. GATA-3 Inhibits IL-12-Induced Th1
Development by an IL-4-Independent Mech-
anism
(A) Splenocytes from IL-4 (2/2) DO11.10 TCR-
transgenic mice were activated as described
above and infected after 1 day with control
(GFP-RV) or GATA-3-expressing (GATA3-RV)
retrovirus. Infected cells were purified by
sorting GFP1 T cells on day 7 and as de-
scribed in Figure 2 and GATA-3 expression
confirmed by Western (Figure 2D). Cytokine
production was measured by ELISA from su-
pernatants taken 48 hr after stimulation.
(B) Wild-type (WT) or IL-4-deficient (IL-
4(2/2)) DO11.10 T cells infected with GFP-
RV or GATA3-RV and purified as described
above. On day 7, T cells were stimulated with
IL-12 (10 U/ml) or IL-18 (50 ng/ml) or plate-
bound anti-CD3 MAb (5 mg/ml) as indicated.
At 48 hr, supernatants were harvested and
IFNg determined by ELISA. The asterisks indi-
cate that the IFNg was less than 3 ng/ml.
Similar results were obtained in two addi-
tional independent experiments.
production was simply the result of increased IL-4 pro- whereas TNFa showed approximately 5- to 10-fold inhi-
bition (Figure 4A, lanes 1 and 2). As before, this inhibitionduction, we repeated these experiments with IL-4-defi-
cient DO11.10 T cells (Figure 3). Maintaining GATA-3 occurred independently of IL-4, since these effects were
identical when repeated using IL-4-deficient DO11.10 Texpression in IL-12-treated IL-4-deficient DO11.10 T
cells completely inhibited IFNg production compared to cells (Figure 4A, lane 5). In addition, these experiments
confirmed previously reported augmentation of severalcontrol cells (Figure 3A, upper panel). Inhibition occurred
even though GATA-3 could not induce IL-4 in these cells Th2-specific cytokines by GATA-3, including the aug-
mentation of IL-4 (Figure 4A, lane 7) and IL-6 (lane 2).(Figure 3A, lower panel), suggesting an IL-4-indepen-
dent mechanism, such as by blockade of some intrinsic However, in contrast to a previous report that IL-5, and
IL-13 were not influenced by GATA-3 (Zheng and Flavell,signaling pathway or transcription factor.
IFNg production was recently shown to be induced 1997), we find augmentation of mRNA for each of these
cytokines, even in IL-4-deficient DO11.10 T cells, sug-not only by TCR but induced synergistically by IL-12 and
IL-18 (Okamura et al., 1995; Robinson et al., 1997). Thus, gesting a direct role of GATA-3, rather than indirectly
inducing these Th2 cytokines via IL-4 production. Thesewe asked whether GATA-3 might differentially interfere
with these pathways. We tested whether GATA-3 inhib- findings extend the previous findings for GATA-3 in con-
trolling Th2 cytokine expression, while demonstrating aited IFNg production stimulated by IL-12 and IL-18, in
addition to anti-CD3, in both wild-type and IL-4-deficient novel IL-4-independent inhibition of IL-12-induced Th1
development.DO11.10 T cells (Figure 3B). GATA-3 expression inhib-
ited all modes of IFNg induction, TCR-dependent and Since some GATA-3-induced cytokines besides IL-4
could potentially inhibit IFNg production, we asked ifcytokine-dependent, in both wild-type (Figure 3B, upper
this inhibition was dependent on the extracellular milieupanel) and IL-4-deficient (lower panel) DO11.10 T cells,
or rather could act in a cell-autonomous manner. Bywhereas control T cells showed IFNg production in re-
analyzing IFNg production at the single-cell level, wesponse to both IL-12/IL-18 treatment and to anti-CD3.
compared intracellular IFNg production in DO11.10 T
cells that were either infected or uninfected by retrovirus
GATA-3 Inhibits IL-12-Induced IFNg Production while developing in the same cell culture induced to
by a Cell-Intrinsic Mechanism undergo Th1 development (Figure 4B). Three-color FACS
As a transcription factor, GATA-3 could potentially aug- analysis was used to discriminate whether T cells had
ment or repress numerous cytokines. Thus, we exam- been infected with retrovirus or not and to determine
ined the effect of GATA-3 on a panel of Th1- and Th2- the level of intracellular IFNg production (Figure 4B).
specific factors using RNase protection (Figure 4A). Infection of T cells by GFP-RV control virus did not
Again, substantial reduction in IFNg production occurred diminish IFNg production of infected T cells compared
in GATA-3-expressing Th1 cells relative to GFP-RV con- to uninfected T cells (Figure 4B, left panel). In contrast,
trols. This also implies that the inhibition of IFNg is at infection of T cells by GATA-3-expressing retrovirus sig-
the level of transcription, or possibly mRNA stability. nificantly reduced intracellular IFNg production of the
Importantly, three other Th1-specific cytokines, tumor infected T cells but not the uninfected T cells in the same
necrosis factor a (TNFa), TNFb, and lymphotoxin b (LTb) culture (Figure 4B, right panel). This result suggests that
were also significantly inhibited by maintenance of despite augmentation in certain Th2-type cytokines in-
GATA-3 in IL-12-induced Th1 development (Figure 4A). duced by GATA-3, the inhibition of IL-12-induced IFNg
is largely mediated by GATA-3 directly within the T cell.TNFb and LTb showed virtually complete repression,
IL-4-Independent Th1 Repression by GATA-3
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Figure 4. GATA-3 Affects Expression of Sev-
eral Cytokine Genes in IL-12-Induced Th1
Cells by an IL-4-Independent Mechanism
(A) Primary wild-type (WT) or IL-4(2/2)
DO11.10 T cells infected with control (GFP-
RV) or GATA-3-expressing (GATA3-RV) virus
induced under Th1 or Th2 conditions as indi-
cated were prepared as described above. T
cells purified by sorting were later stimulated
by PMA and ionomycin for 4 hr as described
(Szabo et al., 1993) RNA purified, and RNase
protection done as described in Experimental
Procedures.
(B) Primary T cells from DO11.10 TCR-
transgenic mice were stimulated using 0.3
mM OVA peptide and infected with control
(GFP-RV) or GATA-3-expressing (GATA3-RV)
virus on day 1. On day 7, intracellular IFNg
assay was performed as described in the Ex-
perimental Procedures. Data are presented
as two-color dot plots showing GFP expres-
sion (FL1) versus intracellular IFNg produc-
tion (FL2) of events gated on expression of
CD4 (FL3).
However, we cannot rule out a minor non-cell-intrinsic infection of a fully differentiated Th1 clone, 3F6 (Figure
5). Cells infected with GATA-3-expressing or GFP con-component with this experiment.
trol retroviruses were purified by cell sorting for GFP
expression 6 days following infection, expanded for 1GATA-3 Inhibition of IL-12-Induced IFNg Is Limited
week, and cytokines analyzed by ELISA. As before, in-to an Early Developmental Window
fection of primary DO11.10 T cells on day 1 inhibited theGATA-3 could act to directly repress IFNg transcription
IL-12-induced Th1 development, with nearly completeor could act only developmentally, perhaps by interfer-
inhibition of IFNg production and 40% augmentation ofing with a Stat4-dependent development process. To
IL-4 production (Figure 5A, upper left and lower leftdistinguish these possibilities, we asked at what stages
panels). In contrast, when Th1 development was im-of Th1 development GATA-3 could inhibit IFNg produc-
posed first for 7 days and T cells then infected on daytion. We therefore extended our previous retroviral infec-
8, the GATA-3-expressing retrovirus produced only ation experiments to include infection on day 1, as before,
but also on day 8 after primary T cell development and 20% reduction in IFNg production relative to control T
Immunity
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Figure 5. GATA-3 Does Not Directly Repress
IFNg Production in Differentiated Th1 Cells
(A) Primary T cells from wild-type or IL-4-defi-
cient IL-4(2/2) DO11.10 mice were activated
under Th1 or Th2 conditions as indicated, in-
fected with control (GFP-RV; closed bars) or
GATA3-expressing (GATA3-RV; open bars)
virus on day 1 (left panels), or restimulated on
day 7 and infected on day 8 (middle panels) as
indicated. Th1 clone (3F6) was activated by
0.3 mM OVA and APC (Experimental Proce-
dures) and infected after 1 day with GFP-RV
or GATA3-RV as indicated. All populations
were purified by cell sorting on day 6 after
infection and restimulated as described above.
48 hr supernatants were collected and cyto-
kines determined by ELISA.
(B) GATA-3 expression in the day 8 infected
T cell population after cell sorting was exam-
ined by Western analysis as described in Fig-
ure 2.
(C) A luciferase base reporter construct con-
taining 200 base pairs of proximal IFNg pro-
moter cotransfected with CMV-Renilla plas-
mid and with either GFP-RV or GATA3-RV
into EL4 cells (Experimental Procedures) as
indicated. Cells were stimulated with (closed
bars) or without (open bars) PMA and iono-
mycin for 4 hr as described and luciferase
activity determined (Szabo et al., 1993). Trans-
fection was normalized by CMV-Renilla and
data represent fold-induction compare to the
unstimulated GFP-RV vector transfection.
cells infected with GFP-RV (Figure 5A, middle panels). larger and smaller IFNg promoter constructs, including
a 3 kilobase genomic promoter region (data not shown).This 20% inhibition of IFNg production was also seen
in IL-4-deficient T cells. Significantly, under these condi- We conclude that GATA-3 is unlikely to exert direct re-
pression of the IFNg promoter but rather may modify ations, no detectable increase in IL-4 production was
seen (Figure 5A, lower middle panel). Finally, the infec- developmental program whose actions are temporally
restricted.tion of 3F6 by GATA-3 retrovirus produced no detectable
reduction in IFNg and, notably, no increase in IL-4 pro-
duction (Figure 5A, right panels). Again, GATA-3 protein GATA-3 Inhibits IL-12 Signaling by Repressing
IL-12R b2 Expressionexpression was confirmed by Western analysis for the
day 8 infection (Figure 5B) and 3F6 (data not shown), IL-4-deficient DO11.10 T cells infected on day 1 of pri-
mary antigen activation with the GATA-3 retrovirus orsuggesting that the reintroduction of GATA-3 into T cells
after Th1 development has occurred but does not result GFP-RV control were purified by cell sorting for GFP-
positive cells and expanded and analyzed for functionalin inhibition of IFNg or the augmentation of IL-4 pro-
duction. IL-12 signaling by EMSA (Figure 6A). For T cells infected
by GFP-RV control retrovirus, treatment by IL-12 in pri-Penix and colleagues have suggested GATA-3 may
augment IFNg via a cis-acting element in the proximal mary activation produced cells exhibiting the expected
IL-12-induced Stat4 complex binding the M67 SIE probepromoter (Penix et al., 1993). Our results suggest GATA-3
may inhibit IFNg production. Therefore, we asked whether (Figure 6A, lane 4) (Jacobson et al., 1995). In contrast,
for T cells infected with GATA-3 retrovirus, treatment bythe GATA-3 expression could augment or inhibit lucifer-
ase activity of an IFNg promoter construct that includes IL-12 during primary activation produced cells that failed
to show IL-12-induced Stat4 complexes (Figure 6A, lanethe proposed GATA-3 target sequence (Figure 5C). The
IFNg reporter construct was cotransfected into EL-4 4). Because the IL-12R b2 subunit is regulated in Th1/
Th2 development (Szabo et al., 1995, 1997), we askedcells (Szabo et al., 1993) with either GATA-3 retrovirus or
GFP-RV control. Transfection efficiency was normalized if GATA-3 expression influenced its expression using
Northern analysis (Figure 6B). We found that IL-12-by cotransfection of a CMV promoter-Renilla luciferase
construct. GATA-3 had minimal effects on IFNg pro- induced Th1 cells infected by GATA-3 retrovirus on day
1 of primary activation later showed complete absencemoter activity (Figure 5C). No inhibition was seen by
GATA-3 for this reporter (Figure 5C) or for a series of of IL-12Rb subunit mRNA, in contrast to IL-12-treated
IL-4-Independent Th1 Repression by GATA-3
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Figure 6. GATA-3 Inhibits IL-12 Signaling and Represses IL-12R b2 Subunit mRNA Expression
(A) IL-4(2/2) DO11.10 T cells were infected with GFP-RV or GATA-3-RV retrovirus and purified and expanded as described in Figure 3. The
indicated T cells were left untreated (-) or treated (1) with IL-12 (10 U/ml) for 30 min, nuclear extracts prepared and examined by EMSA using
the m67 SIE probe for Stat4 activation, or Ea probe to control for extract.
(B) RNA (10 mg/lane) from T cells as described in Figure 4 were analyzed by Northern using IL-12R b2 cDNA (106 cpm/ml), stripped and
reprobed with GAPDH as described to control for RNA integrity. T cells infected by GFP-RV or GATA3-RV on day 8 as described in Figure 5
were restimulated by OVA and APCs and after 7 days either (C) total RNA purified as described in Figure 4 and Northern analysis for IL-12Rb2
or GAPDH done or (D) stimulated with plate-bound anti-CD3 MAb (5 mg/ml) and IL-12 (10 U/ml) as indicated and 48 hr supernatants harvested
and IFNg measured by ELISA.
T cells infected by the GFP control virus. GATA-3 inhib- inhibits IL-12 receptor expression in developing Th2
cells. This predicts a reciprocal expression pattern ofited IL-12R b2 expression in IL-4-deficient DO11.10 T
cells (Figure 6B, lane 5), consistent with the results these genes during Th1 and Th2 development. A kinetic
analysis of GATA-3 and IL-12 R b2 mRNA between dayabove.
Surprisingly, inhibition of IL-12R b2 mRNA by GATA-3 1 and 5 supports this prediction (Figure 7). In primary T
cells induced toward Th2 development, GATA-3 mRNAwas evident even in IL-12-treated T cells that were in-
fected on day 8 after primary activation (Figure 6C), a appears induced by 24 hr, whereas in Th1 development,
IL-12R b2 mRNA is just detectable at 24 hr but is signifi-situation where we previously found no inhibition of IFNg
production (Figure 5). Because by day 8 these T cells cantly higher at 48 hr. Notably, although GATA-3 mRNA
is highest at 48 hr, we observe detectable IL-12R b2have already been exposed to IL-12 for 7 days before
infection, it is possible that the developmental action of mRNA at both 48 and 72 hr even in Th2 conditions, but
which declines after this time. These results suggestStat4 had already occurred to allow TCR inducible IFNg
transcription. Thus, to test the functional significance
of GATA-3-induced down-regulation of IL-12R b2 in the
day 8 infection, we examined the IFNg production in
response to IL-12 in the presence or absence of anti-
CD3 (Figure 6D). As expected, anti-CD3-induced IFNg
production was unaffected by GATA-3 in T cells infected
on day 8 (Figure 6D, lower panel), either in the presence
or absence of IL-12. However, treatment of T cells by
IL-12 alone can elicit a small amount of IFNg production
(Figure 6D, upper panel), but this occurs only in T cells
infected on day 8 with the control GFP virus and not
with GATA-3-expressing retrovirus. Thus, reintroduction
of GATA-3 into differentiated Th1 cells can inhibit IL-
12R b2 expression and block subsequent IL-12-induced
Figure 7. GATA-3 and IL-12R b2 mRNA Expression during Earlyresponses, but TCR-induced IFNg production remains
Stages of Th1 and Th2 Development
intact presumably because the developmental effects
T cells from DO11.10 TCR transgenic mice were activated usingof Stat4 have already occurred to allow TCR-induced
0.3 mM OVA peptide and APCs under either Th1- or Th2-inducing
IFNg production. conditions (Experimental Procedures), harvested at indicated times,
The above results imply that IL-12 represses GATA-3 total RNA prepared and analyzed for GATA-3, IL-12Rb2 and HPRT
expression by Northern analysis.expression in developing Th1 cells and that GATA-3
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that some IL-12 b2 mRNA is expressed early during primary T cells, even under Th1-inducing conditions,
led to augmentation of IL-4. However, reexpression ofTh2 development between days 2 and 3 despite early
GATA-3 induction, which could potentially allow IL-12 to GATA-3 in T cells that had developed in Th1-inducing
conditions for 8 days did not lead to detectable IL-4repress GATA-3 if exposure occurred during this period.
production, despite clear demonstration of GATA-3 pro-
tein expression. Thus, the mechanism of GATA-3 aug-
Discussion mentation of IL-4 expression may involve processes that
are temporally restricted or require cooperation with
This study makes several novel observations. First, unidentified factors.
GATA-3 acquires a Th2-specific expression not simply This report also suggests that GATA-3 inhibits Th1
from being induced by IL-4 but from being actively re- development through a repression of IL-12 signaling
pressed by IL-12. This repression of GATA-3 mRNA by that is IL-4-independent. While GATA factors typically
IL-12 involves Stat4. Next, maintenance of GATA-3 ex- are thought of as positive regulators of gene expression,
pression in developing T cells strongly inhibits IL-12- this is not always the case. The pannier (pnr) gene, a
induced Th1 development, not simply as an indirect Drosophila melanogaster protein belonging to the GATA
effect of augmenting IL-4 production but rather by a family, influences expression of the achaete (ac) and
cell-autonomous mechanism occurring independently scute (sc) genes (Ramain et al., 1993; Haenlin et al.,
of IL-4. However, introduction of GATA-3 into a differen- 1997) and may act either as a repressor or activator
tiated Th1 cell does not inhibit IFNg production, and depending on association with other factors such as
GATA-3 does not directly repress the IFNg promoter. extramacrochaetae (emc) (Heitzler et al., 1996). During
Rather, the inhibition by GATA-3 of IL-12-induced Th1 the first week after primary T cell activation, IL-12-induced
development is limited to the first week of primary T cell Stat4 activation participates in the Th1 developmental
activation. We observe that GATA-3 represses IL-12R program in CD41 T cells (Kaplan et al., 1996; Thierfelder
b2 mRNA expression, thereby preventing IL-12 signaling et al., 1996). We propose that GATA-3 and IL-12 signal-
during an early developmental window and blocking Th1 ing exert mutually antagonistic effects on each other,
development. This mechanism explains the previously with GATA-3 repressing IL-12Rb2 expression and IL-12
described extinction of IL-12R b2 mRNA during Th2 signaling repressing GATA-3 expression. This mecha-
development. nism could explain why maintenance of GATA-3 during
Recently, several studies have analyzed the transcrip- the first 7 days of Th1 induction leads to a significant
tional basis for Th subset-specific expression of various inhibition of IFNg production. Reexpression of GATA-3
cytokine genes. The transcription factors c-Maf (Ho et on day 8 by retrovirus fails to reduce IFNg production,
al., 1996) and GATA-3 (Zheng and Flavell, 1997) were since the Stat4-dependent program that allows TCR-
both identified as Th2-specific cytokines, with c-Maf driven IFNg production in CD41 T cells has already taken
being shown to interact directly with the IL-4 proximal place.
promoter and having actions relatively restricted to the Mutual repressive antagonism between paired signal-
IL-4 but not the IL-5 gene. In contrast, GATA-3 was ing pathways is a common theme in lineage specification
demonstrated to be a Th2-specific factor that may act and development. In Drosophila development, neuroec-
on other cytokine genes, particularly IL-5 (Zhang et al., toderm determination is influenced by Notch signaling,
1997; Lee et al., 1998). GATA family transcription factors where a lateral inhibition mechanism of ligand expres-
regulate many lineage and cell-specific processes. sion and fate determination may stabilize local diver-
GATA-1 and GATA-2 regulate development of the ery- gence of cell differentiation (Artavanis-Tsakonas and
throid and megakaryocytic lineages (Weiss and Orkin, Simpson, 1991; Greenwald and Rubin, 1992; Kopan and
1995; Wu et al., 1995; Maeno et al., 1996; Melotti and Cagan, 1997; Crowe et al., 1998; Rooke and Xu, 1998).
Calabretta, 1996; Takahashi et al., 1997). GATA-3 ap- Similar mechanisms potentially involving Notch partici-
pears to play roles in nervous system and fetal hemato- pate in gd/ab and CD41/CD81 T cell lineage divergences
poetic development (Pandolfi et al., 1995) as well as in (Robey and Fowlkes, 1998). Another example of repres-
early thymocyte development (Hattori et al., 1996; Ting sion in lineage specification appears in the molecular
et al., 1996). GATA-3 is the only GATA factor expressed regulation of the CD41 and CD81 coreceptor genes dur-
in T lymphocytes, and its regulation is complex (Lieuw ing thymocyte maturation from double-positive precur-
et al., 1997). T cell±specific DNase I hypersensitive sites sors (Sawada and Littman, 1991; Ellmeier et al., 1997).
were identified as far as 10.7 kb upstream of the tran- In Th1/Th2 development, mutually antagonistic signals
scriptional start of GATA-3, but the functional role in are seen at several levels. At the gross cytokine level,
directing expression has not been verified (Lieuw et al., IL-12 and IL-4 exert mutually antagonistic effects on
1997). To date, the basis for the Th2-specific T cell ex- their production. A squelching mechanism between dis-
pression of GATA-3 has not been determined. This re- tinct STAT factors could underlie cross inhibition, but
port suggests that GATA-3 expression is augmented by the immediate target genes influenced by Stat4 and
IL-4 via Stat6 (Figure 1C) but that full Th2 specificity Stat6 are not clearly identified at present. This study
involves a repression in Th1 cells that requires IL-12 and provides evidence that GATA-3 and the IL-12 receptor
Stat4 to become complete (Figures 1A and 1B). pathway exert mutual antagonistic effects on each oth-
One surprising result of the present study was that er's expression, representing an unstable situation that
GATA-3 expression in T cells is not sufficient for IL-4 pro- diverges to the stable dominance of one and extinction
duction as previously suggested (Zheng and Flavell, 1997). of the other, generating either a Th1 or Th2 cytokine
profile.Expression of GATA-3 continuously after activation of
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Experimental Procedures RNA, Northern Blots, and RNase Protection Assay
Total RNA was isolated by RNeasy kit (QIAGEN), 10 mg/lane sepa-
rated by electrophoresis and transferred to Zeta Probe membraneMice, Cytokines, and Antibodies
Stat1-, Stat4-, and Stat6-deficient mice were provided by Dr. R. D. (BioRAD). 106 cpm/ml probe was used for Northern hybridization.
The GATA-3 probe was 1.5 kb cDNA above. IL-12Rb2 chain probe,Schreiber (Meraz et al., 1996), Dr. J. N. Ihle (Thierfelder et al., 1996),
and Dr. M. J. Grusby (Kaplan et al., 1996), respectively, and IL- GAPDH, or HPPRT probes have been previously described (Szabo
et al., 1997). The mCK-1 and mCK-3 multi-probe template sets (Phar-4(2/2) DO11.10 TCR-transgenic mice were from Dr. O. Kanagawa.
Stat1- and Stat4-deficient mice were backcrossed three times to Mingen) were used for multiple cytokine gene RNase protection
assays. Total RNA (2 mg/sample) was applied and RNase protectionDO11.10 TCR-transgenic mice (Murphy et al., 1990) before inter-
breeding to generate Stat1(2/2) and Stat4(2/2) H-2d DO11.10 TCR- was performed following the manufacturer's method (PharMingen).
transgenic experimental animals.
Recombinant human IL-2 was provided by Takeda (Osaka, Japan), Reporter Construct and Luciferase Assay
murine rIL-12 by Genetics Institute (Cambridge, MA), murine rIFNg A 3.5 kb murine IFNg promoter was provided by Dr. H. Fox (Scripps,
by Genentech (San Francisco, CA), and murine rIL-18 from Research La Jolla, CA) (Fox et al., 1991). 59 oligonucleotides with SalI tails
Diagnostics, Inc. (Flanders, NJ). Murine rIL-4 was generated from and 39 oligonucleotides with BamHI tails were used to generate a
transfected P815 mastocytoma cells as high-titer culture superna- series of 59-truncations of the IFNg promoter by PCR and cloned
tant. Monoclonal anti-mIFNg (H22) was from Dr. R. D. Schreiber; into SalI/BglII digested pBS-Luc (Szabo et al., 1993). The CMV-
monoclonal anti-IL-4 (11B11) (Ohara and Paul, 1985), anti-IL-12 promoter was used to express Renilla luciferase (Promega) for nor-
(Tosh) (Tripp et al., 1994), and anti-CD3 (500A2) were purified by malization of transfection. EL-4 cells (107) were transfected with 20
affinity chromatography under endotoxin-free conditions from cul- mg of IFNg reporter construct, 10 mm GFP-RV or GATA-3-RV, and
ture supernatant. 500A2 cell line was a gift of Dr. J. P. Allison (Berke- 1 mg CMV-Renilla luciferase construct in 1.2 ml RPMI, electropor-
ley, CA). ated (960 mF, 280 V) as described (Szabo et al., 1993). At 12 to 14
hr, cells were left untreated or activated by 50 ng/ml PMA and 1 mM
ionomycin as indicated for 4 hr and luciferase measure as describedT Cell Activation and Phenotype Differentiation
(Szabo et al., 1993).Splenocytes from TCR-transgenic mice were purified on a density
gradient (Histopaque-1119, Sigma) and activated by chick oval-
Western Blot Analysis and Electrophoreticbumin peptide 323±339 (OVA) at 3 3 106 cells/ml in IMDM media.
Mobility Shift AssayConcanavalin A (1 mg/ml) was used to activate T cells from
T cells (107) stimulated as indicated were lysed in 30 ml cell lysisStat6(2/2) mice (3 3 106 cells /ml). IL-12 (10 U/ml) and anti-IL-4
buffer (5% SDS, 0.5 M Tris [pH 6.8], 0.5 mM EDTA, 1 mM DTT, 1(11B11, 10 mg/ml) were added for Th1 development, and IL-4 (100
mM PMSF, and 10 mg Leupeptin) for 10 min at room temperature,U/ml) and anti-IL-12 (Tosh, 3 mg/ml) for Th2 development. For ret-
centrifuged at 100,000 3 g for 10 min, supernatants resolved byroviral infection experiments, T cells were harvested on day 7 after
SDS-PAGE, and transferred to nitrocellulose. Blots were probedprimary activation and purified by cell sorting for GFP expression.
with murine monoclonal anti-GATA-3 antibody (Santa Cruz, 1:3000)For passage, T cells were harvested 7 days after the last activation
and developed as described (Guler et al., 1997). Nuclear extractsby OVA, washed, and stimulated with OVA peptides (0.3 mM) at 1.25
were prepared as described (Jacobson et al., 1995). 3 mg nuclear3 105 cell/ml with irradiated BALB/c splenocytes (2000 rads, 2.5 3
extracts were incubated on ice with 32P-labeled m67 or Ea probe106 cells /ml) with addition of the indicated cytokines. For ELISA,
(2 3 105 cpm) in binding buffer (Szabo et al., 1993) with 1 mg poly-supernatants were collected after 48 hr and measured as described
dIdC for 30 min before addition of gel loading buffer and electropho-(Hsieh et al., 1993a). The Th1 clone 3F6 derived from DO11.10 TCR
resis at room temperature on polyacrylamide gels.transgenic T cells (Jacobson et al., 1995) was maintained by bi-
weekly antigen stimulation as above. For anti-CD3 stimulation, 5
mg/ml anti-CD3 antibody (500A2) in PBS was coated overnight onto Intracellular IFNg Staining and FACS Analysis
Intracellular staining was based on the method of Assenmacher et48-well plates (1 ml/well) at 48C and washed twice with PBS and T
cells applied (2.5 3 105 cells /ml) with cytokines as indicated in the al. (1994). Primary DO11.10 T cells were infected with GFP-RV or
GATA-3 retrovirus as described above. On day 7 after primary activa-figure legends.
tion, T cells were stimulated with PMA (50 ng/ml) and ionomycin (1
mM) for 2 hr and 10 mg/ml Brefeldin A (Epicenter Technology) added
Retroviral Constructs and Retroviral Transfection for an additional 2 hr. T cells were harvested, washed with PBS,
To generate the GFP-RV vector, a 600 bp EcoRI-NcoI fragment suspended in 200 ml PBS, fixed for 20 min with 4% paraformalde-
comprising the encephalomyocarditis virus internal ribosomal entry hyde, washed twice with PBS in 2% fetal calf serum (FCS), and
sequence (IRES) was isolated from pCITE-1 (Novagen) and a 700 suspended in PBS, 2% FCS, and 0.5% saponin (Sigma) for 10 min.
bp NcoI-EcoRI humanized GFP allele hGFP-S65T (Clonetech) con- PE-conjugated anti-murine IFNg and Cy-Chrome-conjugated anti-
taining an additional solubility point mutation (163 V.T) were ligated murine-CD4 (PharMingen) were added for 30 min, the cells washed
into the EcoRI site of pBluescript II SK(-) (Stratagene) in a trimolecu- twice in saponin/FCS/PBS and analyzed on a FACSCalibur (Becton
lar ligation. A 1.3 kb XhoI-BamHI from this plasmid was used to Dickinson). Gates for GFP (FL1) positive cells were determined using
replace the 1.3 kb pgk-neomycin cassette MSCV2.2 retroviral vector nontransfected controls.
(Hawley et al., 1994). GATA-3 cDNA was generated by PCR using
R/M GATA-3 (a gift of Dr. J. D. Engel) (Ko et al., 1991) as template. The
Acknowledgmentsprimers used were GAATTCGTCGACGCTCTGCCTCTCTAACCCAT
and GAATTCGTCGACGGACATGGAGGTGACTGCGGA. The SalI di-
We thank J. D. Engel (Evanston, IL) for the R/M GATA-3 plasmid,gested PCR product was ligated to XhoI digested GFP-RV vector.
A. Winoto (Berkeley, CA) for providing the human version of theThis GATA-3-RV plasmid was confirmed by sequencing. The KRR
KRR GATA-3 mutant, and Debbie Wyman for excellent cell sorting.mutation of GATA-3 (Smith et al., 1995) was made using the primers
This work was supported by National Institutes of Health grantsCCCCTTATCAAGCCCGCGGCAGCGCTGTCGGCAGCAAGG and
AI31238 and AIDK39676. K. M. M. is an Associate Investigator ofCCTTGCTGCCGACAGCGCTGCCGCGGGCTTGATAAGGGG, which
the Howard Hughes Medical Institute.was confirmed by complete sequencing.
Phoenix-Eco packaging cell line (gift of Dr. G. Nolan, Stanford
Received September 2, 1998; revised October 22, 1998.CA) were transfected according to Dr. Nolan's protocol. Primary T
cells were activated as described above and infected after 24 hr
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